Biomedical Engineering Reference
In-Depth Information
Coscelli A, Shum M (2004) An empirical model of learning and patient spillovers in new drug
entry. J Econ 122(2):213-246
Currie GR, Park S (2002) The effects of advertising and consumption experience on the demand
for antidepressant drugs. Working paper, University of Calgary
Danzon PM, Chao LW (2000) Cross-national price differences for pharmaceuticals: how large,
and why? J Health Econ 19(2):159-195
De Laat E, Windmeijer F, Douven R (2002) How does pharmaceutical marketing infl uence
doctors' prescribing behaviour? CPB Netherlands' Bureau for Economic Policy Analysis, The
Hague
Dekimpe MG, Hanssens DM (1999) Sustained spending and persistent response: a new look at
long-term marketing profi tability. J Mark Res 36(4):397-412
Desiraju R, Nair H, Chintagunta P (2004) Diffusion of new pharmaceutical drugs in developing
and developed nations. Int J Res Mark 21(4):341-357
Families USA (2001) Off the charts: pay, profi ts and spending by drug companies. Families USA
Publication 01-104
Families USA (2002) Profi ting from pain: where prescription drug dollars go. Families USA
Publication 02-105
Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand
for prescription drugs? J Mark Res 47(1):103-121
Fischer M, Leefl ang PSH, Verhoef PC (2010) Drivers of peak sales for pharmaceutical brands.
Quant Mark Econ 8(4):429-460
Fok D, Franses PH (2007) Modeling the diffusion of scientifi c publications. J Econ
139(2):376-390
Frenzel A, Grupp H (2009) Using models of innovation diffusion to forecast market success:
a practitioners' guide. Res Eval 18(1):39-50
Gatignon H, Weitz B, Bansal P (1990) Brand introduction strategies and competitive environ-
ments. J Mark Res 27(4):390-401
Gönül FF, Carter F, Petrova E, Srinivasan K (2001) Promotion of prescription drugs and its impact
on physicians' choice behavior. J Mark 65(3):79-90
Gonzalez J, Sismeiro C, Dutta S, Stern P (2008) Can branded drugs benefi t from generic entry?
The role of detailing and price in switching to non-bioequivalent molecules. Int J Res Mark
25(4):247-260
Guseo R, Guidolin M (2009) Modelling a dynamic market potential: a class of automata networks
for diffusion of innovations. Technol Forecast Soc Change 76(6):806-820
Haaijer-Ruskamp FM, Denig P (2001) Invloeden bij het Kiezen van Geneesmiddelen.
Geneesmiddelenbulletin 35(4):37-42
Hahn M, Park S, Krishnamurthi L, Zoltners AA (1994) Analysis of new product diffusion using a
four-segment trial-repeat model. Mark Sci 13(3):224-247
Hellerstein JK (1998) The importance of the physician in the generic versus trade-name prescrip-
tion decision. Rand J Econ 29(1):108-136
Helsen K, Schmittlein DC (1993) Analyzing duration times in marketing research: evidence for
effectiveness of hazard models. Mark Sci 12(4):395-414
Hurwitz MA, Caves RE (1988) Persuasion or information—promotion and the shares of brand
name and generic pharmaceuticals. J Law Econ 31(2):299-320
Iizuka T, Jin GZ (2005) The effect of prescription drug advertising on doctor visits. J Econ Manag
Strategy 14(3):701-727
IMS (2010) IMS health forecasts global pharmaceutical market growth of 5-7 percent in 2011,
reaching $800 billion.
http://www.imshealth.at/portal/site/ims/menuitem.d248e29c86589c9c3
.
Accessed 11 Nov 2011
Jain DC (1992) Marketing mix effects on the diffusion of innovations. Working paper, Kellogg
Graduate School of Management, Northwestern University
Jain DC, Vilcassim NJ (1991) Investigating household purchase timing decisions: a conditional
hazard function approach. Mark Sci 10(1):1-23
Search WWH ::
Custom Search